Angiodynamics reports fiscal year 2026 first quarter financial results; med tech growth of 26.1% drives continued momentum

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2026, which ended august 31, 2025. fiscal year 2026 first quarter highlights   quarter ended august 31, 2025 pro forma* yoy growth net sales $75.7 million.
ANGO Ratings Summary
ANGO Quant Ranking